Loading clinical trials...
Loading clinical trials...
A Phase IIa Randomized, Partially Blinded Trial of Telaprevir (VX-950) in Treatment-Naive Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection
Conditions
Interventions
Telaprevir
Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)
+1 more
Locations
7
France
Clichy, France
Créteil, France
Lyon, France
Paris, France
Vandœuvre-lès-Nancy, France
Stockholm, Sweden
Start Date
December 1, 2007
Primary Completion Date
June 1, 2008
Completion Date
May 1, 2009
Last Updated
June 17, 2013
NCT05870969
NCT03987503
NCT04382404
NCT01226797
NCT00062816
NCT04774107
Lead Sponsor
Tibotec BVBA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions